Russia Announces Breakthrough mRNA Cancer Vaccine ‘Enteromix’ with 100% Safety in Trials
Source: facebook
According to a recent announcement by Russia’s Federal Medical and Biological Agency (FMBA), Russia’s mRNA-based cancer vaccine Enteromix has achieved 100% safety and efficacy in clinical trials.
According to the FMBA, the vaccine was developed using the same mRNA technology as the COVID-19 vaccine and is designed to train the immune system to recognize and eliminate cancer cells, making it a safer and more intelligent alternative to traditional cancer treatments such as chemotherapy. Furthermore, the vaccine is to be personalized for every individual.
The clinical trials involved 48 volunteers and were conducted by the Russian National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology. The trials showed that the vaccine demonstrated a significant shrinking of tumors and a slowing down of tumor growth. It was also found that the vaccine was safe for repeated use.
According to a post on X by Sputnik, a global wire and digital news service, Veronica Skvortsova, Head of the FMBA, had stated that the first form of the vaccine will be used to treat colorectal cancer, while another version will be developed to treat glioblastoma (brain cancer) and several types of melanoma (skin cancer).
